The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen. Key trials that assess the relative efficacy, safety and resistance profile of 3TC and emtricit...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2021-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen. Key trials that assess the relative efficacy, safety and resistance profile of 3TC and emtricitabine (FTC) are discussed. Clinical use of 3TC and FTC with two tenofovir prodrugs -TDF and tenofovir alafenamide (TAF) - is presented. Recommendations from various international guidelines for the construction of triple and emerging dual regimens are summarised. In conclusion, data suggest the therapeutic equivalence of 3TC and FTC, especially when 3TC is combined with TDF. |
|---|---|
| Item Description: | 2055-6640 10.1016/j.jve.2021.100028 |